These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
209 related items for PubMed ID: 16949795
1. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA. Cell Signal; 2007 Feb; 19(2):401-9. PubMed ID: 16949795 [Abstract] [Full Text] [Related]
2. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Valentini A, Biancolella M, Amati F, Gravina P, Miano R, Chillemi G, Farcomeni A, Bueno S, Vespasiani G, Desideri A, Federici G, Novelli G, Bernardini S. Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798 [Abstract] [Full Text] [Related]
3. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS. Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726 [Abstract] [Full Text] [Related]
4. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L. Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748 [Abstract] [Full Text] [Related]
5. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells]. Song Y, Wu G, Xin DQ, Na YQ. Zhonghua Wai Ke Za Zhi; 2004 Dec 07; 42(23):1453-6. PubMed ID: 15733464 [Abstract] [Full Text] [Related]
6. Regulation of growth hormone receptors in human prostate cancer cell lines. Bidosee M, Karry R, Weiss-Messer E, Barkey RJ. Mol Cell Endocrinol; 2009 Oct 15; 309(1-2):82-92. PubMed ID: 19540305 [Abstract] [Full Text] [Related]
7. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA. Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446 [Abstract] [Full Text] [Related]
8. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Asirvatham AJ, Schmidt MA, Chaudhary J. Prostate; 2006 Jun 15; 66(9):921-35. PubMed ID: 16541417 [Abstract] [Full Text] [Related]
9. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716 [Abstract] [Full Text] [Related]
10. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Xie Y, Wolff DW, Lin MF, Tu Y. Mol Pharmacol; 2007 Jul 15; 72(1):73-85. PubMed ID: 17430995 [Abstract] [Full Text] [Related]
11. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Cancer Res; 1999 Aug 01; 59(15):3821-30. PubMed ID: 10447001 [Abstract] [Full Text] [Related]
12. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ. Prostate; 2005 Apr 01; 63(1):44-55. PubMed ID: 15468165 [Abstract] [Full Text] [Related]
14. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF. Endocr Relat Cancer; 2006 Mar 01; 13(1):151-67. PubMed ID: 16601285 [Abstract] [Full Text] [Related]
15. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B. Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538 [Abstract] [Full Text] [Related]
16. Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells. Kumagai T, Tomari K, Shimizu T, Takeda K. Int J Mol Med; 2006 Feb 01; 17(2):285-91. PubMed ID: 16391828 [Abstract] [Full Text] [Related]
17. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling. Oosterhoff JK, Grootegoed JA, Blok LJ. Endocr Relat Cancer; 2005 Mar 01; 12(1):135-48. PubMed ID: 15788645 [Abstract] [Full Text] [Related]
18. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Oncol Rep; 2004 Jun 01; 11(6):1187-92. PubMed ID: 15138554 [Abstract] [Full Text] [Related]
19. Rap2 regulates androgen sensitivity in human prostate cancer cells. Bigler D, Gioeli D, Conaway MR, Weber MJ, Theodorescu D. Prostate; 2007 Oct 01; 67(14):1590-9. PubMed ID: 17918750 [Abstract] [Full Text] [Related]
20. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ. Prostate; 2005 Apr 01; 63(1):29-43. PubMed ID: 15378522 [Abstract] [Full Text] [Related] Page: [Next] [New Search]